Treatment with the IV P2Y12 inhibitor cangrelor reduced the number of early ischemic events after PCI, primarily MI and stent thrombosis, compared with oral clopidogrel, according to the results of the CHAMPION PHOENIX trial.
“Patients undergoing PCI are at risk of activation of the clotting process, formation of intravascular thrombus and subsequent myocardial infarction,” said Matthew A. Cavender, MD, MPH, interventional cardiologist and assistant professor of medicine in the division of cardiology, in a new article about the study. “As such, adjunctive pharmacology used at the time of PCI is designed to prevent thrombus formation by inhibiting both platelet activation and thrombin formation.”
Read the article published in Cardiology Today.